(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Q1 2023 Earnings Report: KE Holdings and Bath & Body Works Exceed Expectations, Sociedad Química y Minera de Chile Falls Short; Revvity Inks Licensing Deal with AstraZeneca

  • May 18th, 2023
  • 571 views

KE Holdings Inc. (NYSE: BEKE) reported better-than-expected adjusted earnings per share (EPS) for the first quarter of 2023. The company's adjusted EPS stood at $0.43, surpassing the consensus estimate of $0.23. 

In pre-market trading, $BEKE is showing a positive trend. It is currently trading at $16.59, with a gain of $0.29 (+1.78%). .

Similarly, Bath & Body Works, Inc. (NYSE: BBWI) also announced its adjusted EPS for the first quarter of 2023, exceeding market expectations. The company reported an adjusted EPS of $0.33 compared to the consensus estimate of $0.26. 

In pre-market trading, $BBWI is displaying a strong positive momentum. It is currently trading at $36.00, showing a gain of $1.98 (+5.82%)..

On the other hand, Sociedad Química y Minera de Chile S.A. (NYSE: SQM) reported Q1 EPS of $2.63, falling short of the consensus estimate of $3.05.

In pre-market trading, $SQM is facing a slight decline. It is currently trading at $70.00, with a decrease of $2.65 (-3.65%). 

Additionally, before the market opened today, Revvity, Inc. (NYSE: RVTY) made an announcement regarding a new license agreement with AstraZeneca PLC (Nasdaq: AZN). The agreement grants AstraZeneca non-exclusive access to Revvity's proprietary gene editing technology underlying the Pin-point base editing system. This advanced gene editing platform offers a modular approach and a robust safety profile, which could support AstraZeneca's cell therapy research and development initiatives.

Please note that the information provided is based on the given details, and stock prices and market conditions are subject to change throughout the trading day.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments


Warning: Undefined array key "hashid" in /var/www/html/subs/visit_counter.php on line 13